Sanofi India Ltd.
Snapshot View

8599.00 +53.95 ▲0.6%

03 August 2021, 04:00:00 P.M.
Volume: 1,125

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aventispharmaindia.com
Financial Indicators
Market Cap 19,679.78 Cr.
Earnings per share (EPS) 251.88 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 33.92 Trailing Twelve Months Ending 2021-06
Industry PE 32.66 Trailing Twelve Months Ending 2021-06
Book Value / Share 697.04 Trailing Twelve Months Ending 2021-06
Price to Book Value 12.26 Calculated using Price: 8,545.05
Dividend Yield 4.27 Period Ending 2020-12
No. of Shares Subscribed 2.30 Cr. 23,030,622 Shares
FaceValue 10
Company Profile

Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.

Business area of the company

The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Products

Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).

Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)

Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)

Milestones

  • 2013: Sanofi India launches Combiflam Plus.
  • 2013: Sanofi ties up with IDF, PHFI to fight against diabetes among children in India.
  • 2013: Sanofi India inks pact with Suzlon Energy for renewable energy.
  • 2014: Sanofi India - Diabetic Teen from Pune achieves unique feat.
  • 2014: Sanofi partners with Emcure Pharmaceuticals for marketing and distribution of its oncology portfolio in India.
  • 2015: Sanofi delivers 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur to support the immunization of children from five pediatric diseases.
  • 2016: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research.
  • 2018: Sanofi receives positive CHMP opinion for dengue vaccine.
  • 2018: Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure.
  • 2019: Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
  • 2020: Sanofi Completes Acquisition of Synthorx, Inc.
  • 2020: Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
  • 2020: Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.63%
1 Week
+8.03%
1 Month
+11.85%
3 Month
+12.24%
6 Month
+9.02%
1 Year
+3.52%
2 Year
+41.74%
5 Year
+89.22%
9 years 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12
Return on Equity (%) 15.38 20.97 18.70 20.68 17.43 16.87 18.18 18.07 21.39
Return on Capital Employed (%) 22.90 30.75 26.47 30.96 27.51 26.38 28.76 25.75 29.77
Return on Assets (%) 11.27 15.11 12.84 13.88 12.30 9.50 8.37 8.28 9.24

Balance Sheet View Details

Particulars 9 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2019-12 Rs. Cr. 2020-12 Rs. Cr.
Shh. Funds 1,204 1,347 1,486 1,627 1,883 2,026 2,219 2,442 2,119
Non Curr. Liab. 41 63 86 161 156 1,335 1,357 1,124 1,280
Curr. Liab. 387 469 656 617 502 962 1,193 1,674 1,694
Minority Int.
Equity & Liab. 1,631 1,878 2,228 2,405 2,541 4,324 4,769 5,240 5,093
Non Curr. Assets 803 931 965 1,161 966 2,519 2,608 2,141 2,253
Curr. Assets 829 947 1,263 1,244 1,575 1,805 2,162 3,099 2,841
Misc. Exp. not W/O
Total Assets 1,631 1,878 2,228 2,405 2,541 4,324 4,769 5,240 5,093

Profit Loss View Details

Particulars 9 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2019-12 Rs. Cr. 2020-12 Rs. Cr.
Net Sales 1,573 1,809 1,977 2,193 2,367 2,464 2,771 3,071 2,902
Other Income 41 58 64 51 66 81 90 94 90
Total Income 1,614 1,867 2,042 2,245 2,433 2,544 2,861 3,165 2,992
Total Expenditure -1,261 -1,411 -1,639 -1,734 -1,832 -1,926 -2,148 -2,405 -2,189
PBIDT 353 456 403 511 602 618 713 759 803
Interest -1 0 0 0 -2 -1 -1 0 -2
Depreciation -90 -92 -97 -113 -119 -102 -103 -100 -82
Taxation -85 -123 -109 -159 -176 -189 -229 -186 -200
Exceptional Items 25 67 84 -59 -42
PAT 177 265 264 322 304 326 381 414 478

Cash Flow View Details

Particulars 9 years 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2019-12 Rs. Cr. 2020-12 Rs. Cr.
Cash Fr. Operatn. 290 273 265 213 322 435 374 412 611
Cash Fr. Inv. -5 -335 61 36 -155 -79 -73 66 276
Cash Fr. Finan. -90 -105 -122 -147 -180 -188 -197 -183 -810
Net Change 195 -168 205 102 -13 168 104 295 78
Cash & Cash Eqvt 429 261 466 568 554 722 825 1,120 1,197

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 60.40 60.40 60.40 60.40 60.40 60.40 60.40 60.40 60.40
Public 39.60 39.60 39.60 39.60 39.60 39.60 39.60 39.60 39.60
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Slump Sale And Transfer Of The Nutraceuticals Business Of The Company
Please find enclosed announcement related to - Slump Sale and transfer of the Nutraceuticals business of the Company which is self explanatory for your records
Tue, 27 Jul 2021
Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2021
We refer to our letter dated 12th July 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 11.30 a.m. and concluded at 1.45 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2021.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2021 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2021 along with a copy of the Limited Review Report duly signed by the Auditors of the Company.
Thu, 15 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s) details of which are enclosed.

Technical Scans View Details

Mon, 02 Aug 2021
Close Crossing Last Week High Close Crossing Last Week High
Close Crossing Last Month High Close Crossing Last Month High
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 794.85 +2.6%
Divi's Laboratories Ltd. 130,822.92 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,721.20 +0.4%
Cipla Ltd. 74,356.30 927.25 +0.6%
Cadila Healthcare Ltd. 60,574.85 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,317.82 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 30.92 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.06 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%